✦ LIBER ✦

Mechanism of gastric acid hypersecretion in patients with islet cell tumor without hypergastrinemia: Studies in rats

✍ Scribed by Y Song; WY Chey; TM Chang; KY Lee

Book ID: 119755790
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 342 KB
Volume: 113
Category: Article
ISSN: 0016-5085
DOI: 10.1053/gast.1997.v113.pm9322507

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mechanism of gastric acid hypersecretion

Mechanism of gastric acid hypersecretion in patients with islet cell tumors involves potentiation between gastrin and a non-gastrin acid stimulating peptide

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 153 KB

An open-label study of rabeprazole in pa

An open-label study of rabeprazole in patients with Zollinger–Ellison syndrome or idiopathic gastric acid hypersecretion

✍ A. MOROCUTTI; M. MERROUCHE; T. BJAALAND; T. HUMPHRIES; M. MIGNON 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB

Phase II study of thalidomide in patient

Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors

✍ Kimberly A. Varker; Jacqueline Campbell; Manisha H. Shah 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 287 KB

Low Frequency of Autoantibodies to Islet

Low Frequency of Autoantibodies to Islet Cell, Glutamic Acid Decarboxylase, and Second-Islet Antigen in Patients with Gestational Diabetes Mellitus : A Follow-up Study

✍ A. LAPOLLA; D. FEDELE; B. PEDINI; M. G. DAL FRÀ; M. SANZARI; M. MASIN; R. ZANCHE 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 675 KB

Gastric acid secretion by non-gastrin ac

Gastric acid secretion by non-gastrin acid stimulating peptide in islet cell tumor extracts is mediated by release of histamine from gastric ECL cells in rats: Y Song, T-M Chang, KY Lee, WY Chey. University of Rochester Medical Center, Rochester, NY

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 159 KB

Interferon-α-2a with or without 13-cis r

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)

✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin